Published in Blood Weekly, August 26th, 2004
However, the company's stock slumped in early trading because analysts had predicted even stronger earnings.
CSL, one of the world's leading makers of blood plasma products, said it expects net profit of between 210 million Australian dollars (US$147 million) and A$220 million (US$154 million) for fiscal year 2004, up from A$70.4 million the year before.
Profit would be boosted by a gain of A$75 million (US$52.5 million) from the sale of the Animal...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.